Objective: To test whether the mucus layer, luminal digestive enzymes, and intestinal mast cells are critical components in the pathogenesis of trauma shock-induced gut and lung injury. Background: Gut origin sepsis studies have highlighted the importance of the systemic component (ischemia-reperfusion) of gut injury, whereas the intraluminal component is less well studied. Methods: In rats subjected to trauma hemorrhagic shock (T/HS) or sham shock, the role of pancreatic enzymes in gut injury was tested by diversion of pancreatic enzymes via pancreatic duct exteriorization whereas the role of the mucus layer was tested via the enteral administration of a mucus surrogate. In addition, the role of mast cells was assessed by measuring mast cell activation and the ability of pharmacologic inhibition of mast cells to abrogate gut and lung injury. Gut and mucus injury was characterized functionally, morphologically, and chemically. Results: Pancreatic duct exteriorization abrogated T/HS-induced gut barrier loss and limited chemical mucus changes. The mucus surrogate prevented T/HS-induced gut and lung injury. Finally, pancreatic enzyme-induced gut and lung injury seems to involve mast cell activation because T/HS activates mast cells and pharmacologic inhibition of intestinal mast cells prevented T/HS-induced gut and lung injury. Conclusions: These results indicate that gut and gut-induced lung injury after T/HS involves a complex process consisting of intraluminal digestive enzymes, the unstirred mucus layer, and a systemic ischemic-reperfusion injury. This suggests the possibility of intraluminal therapeutic strategies.
T he gut hypothesis of the multiple organ dysfunction syndrome (MODS) has been the subject of intensive investigation for almost 3 decades and has led to the recognition that systemic insults leading to splanchnic hypoperfusion cause subsequent gut injury and ultimately result in a gut-induced systemic inflammatory state, acute lung injury, and MODS. 1 This work has contributed to specific gut-directed therapies such as early enteral nutrition, immunonutrition, and selective digestive decontamination. 2 Mechanistic studies of gut origin sepsis have highlighted the important role of the downstream intestinal ischemia-reperfusion (I/R) injury that results from decreased mesenteric perfusion and the global role of pancreatic digestive enzymes in shock. 3 However, the role of many intraluminal nonbacterial factors remains less well researched and understood. 4, 5 We and others have recently focused attention on these nonbacterial luminal factors that modulate gut I/R injury, with a special emphasis From on the protective role of the intestinal mucus layer [6] [7] [8] and the potentially injurious effects of luminal digestive enzymes. 5, 9, 10 These results have led to the hypothesis that trauma hemorrhagic shock (T/HS)-induced splanchnic hypoperfusion causes oxidative damage to the mucus layer, thereby allowing pancreatic enzymes to reach and autodigest the otherwise protected intestinal mucosa, triggering the gut origin MODS response. However, much work is still required to understand the potential relationships between mucus oxidation, intestinal mucus loss, luminal digestive enzymes, and the pathways by which pancreatic enzymes contribute to T/HS-induced gut injury and inflammation. Consequently, the overall goal of this study was to investigate the role of the intraluminal nonbacterial components of the intestine in T/HS-induced gut injury and gut-induced acute lung injury and potential interactions between the unstirred mucus layer, pancreatic proteases, and mucosal mast cells. The results of this study support the protective role of the mucus layer, indicate that pancreatic proteases contribute to intestinal injury, and suggest an association with mast cell activation and degranulation.
METHODS Animals
Male Sprague-Dawley rats weighing 320 to 400 g were housed under barrier-sustained conditions, at a temperature of 25 • C, with 12-hour light/dark cycles, and acclimated for at least 5 days before experimentation. The rats had free access to water and chow (Teklan 22/5 Rodent Diet W-8640; Harlan Teklad, Madison, WI). All rats were maintained in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals. All animal protocols were approved by the New Jersey Medical School Animal Care Committee.
Experimental Design
Recent studies suggest that T/HS-induced gut injury also involves luminal factors, especially the mucus layer and pancreatic digestive enzymes. [4] [5] [6] In this regard, the mucus layer seems to function as a key protective factor, limiting other factors, especially pancreatic digestive enzymes, from reaching the underlying epithelium and disrupting gut barrier function. The first set of experiments was therefore designed to determine the effect of pancreatic enzymes on the intestinal mucus layer and correlate these changes with gut morphology and barrier function. The goal of the second set of studies was to determine whether high-molecular-weight polyethylene glycol (HMW-PEG), which can function as a mucus surrogate, 11 would protect against T/HS-induced gut injury and gut-derived acute lung injury. HMW-PEG has previously demonstrated to adhere to the intestinal wall, thereby altering surface electric charges, hydrophobicity, and bacterial-host interactions. 11 PEG is a known biologically inert material, is both nontoxic and nonimmunogenic, and prevents adsorption of bioactive agents. 12 Furthermore, in prior in vitro studies specifically evaluating barrier function, HMW-PEG was shown to demonstrate a dose-dependent increase in endothelial cell barrier function. 13 Finally, as mast cells contain protease-activated receptors that could be activated by pancreatic proteases that cross the mucosal barrier, we tested the hypothesis that mast cell inhibition would limit T/HS-induced gut and lung injury. In all groups of animals, these studies were carried out at 3 hours after the end of the T/HS or trauma sham shock (T/SS) period because gut and lung injury is well established at this point. 14 In the first set of studies, rats were divided into 4 groups. The animals were subjected to either T/HS or T/SS, with half of each group receiving either pancreatic duct ligation and cannulation (PDC) or sham PDC. The goal of PDC was to divert pancreatic enzymes from the intestinal lumen. Because it is known that the large sugar moieties within the mucin molecule act as physiologic free radical scavengers 15 and that reactive oxygen and nitrogen species can damage and degrade mucin molecules leading to a loss of mucus viscosity, hydrophobicity, and barrier function, 15, 16 we measured the extent of oxidant stress to the mucus layer and its antioxidant capacity in one set of animals. Mucus oxidant stress was assayed by measuring carbonyl derivatives and nitrated tyrosine residues in the mucus, because these are markers of reactive oxygen and nitrogen reactions. 17, 18 Mucus function was evaluated by measuring the antioxidant activity of the mucus. In a second set of animals, in which mucus collection did not occur, gut barrier function was assessed functionally (intestinal permeability studies) and morphologically by quantifying villous injury and the extent of mucus loss.
In the second study, we tested the hypothesis that administration of a chemical mucin surrogate would ameliorate gut injury and prevent loss of gut barrier function. As the increase in gut permeability observed after T/HS has been implicated in the development of the acute respiratory distress syndrome, our secondary aim was to determine whether the potential gut protective effect of surrogate mucins would attenuate lung injury. Rats were divided into 3 groups: T/SS, T/HS + vehicle (sterile water), and T/HS + mucin surrogate (HMW-PEG). HMW-PEG (15-20 kD) was administered by injection into the duodenum as a 5% solution at a dose of 30 mL/kg during the laparotomy as previously described. 11 Luminal contents were not disrupted or removed during the injection, and this volume of PEG was found in prior studies to be sufficient to reach throughout the duodenum without causing distention. Three hours after resuscitation, at the end of the shock or sham shock period, gut barrier function was assayed functionally [intestinal permeability to FD4 (fluorescein isothiocyanate-dextran, a fluorescent-labeled dextran molecule with an average molecular weight of 3000 to 5000 units), and bacterial translocation to mesenteric lymph nodes) and histologically by the measurement of villous injury. In a second group of rats, lung injury was measured by permeability to Evans blue dye and bronchoalveolar lavage fluid (BALF) leukocyte counts.
In the third study, we tested the hypothesis that T/HS-induced gut injury was associated with mast cell activation and that activated mast cells contribute to T/HS-induced gut and lung injury. Rats were divided into a T/HS group and a T/SS group as previously described. After trauma shock or sham shock, serum and lymph were collected and analyzed for RMCP (rat mast cell protease) II levels, because RMCP II is a mast cell protease specific to enteric mast cells and is a marker of mast cell degranulation. 19 Terminal ileum samples were obtained, and gut injury (villous damage) and the number of mast cells were measured. In subsequent experiments aimed at further testing the role of mast cell degranulation in T/HS-induced gut and lung injury, we measured gut and lung injury in rats receiving either the mast cell stabilizer doxantrazole, which affects both mucosal and connective tissue mast cells, 20 or the mast cell stabilizer ketotifen, which affects only connective tissue mast cells. 21 This study tested the hypothesis that mucosal, but not the connective tissue, mast cell stabilization would be protective. We selected these 2 mast cell agents on the basis of prior studies using an lipopolysaccharide model of I/R gut injury showing that pretreatment with doxantrazole, but not ketotifen, was effective in reducing gut mast cell activation and degranulation. 22 Doxantrazole (25 mg/kg, intraperitoneally) was administered at 2 and 20 hours before T/HS (T/SS) as was ketotifen (20 mg/kg, intraperitoneally). These doses were based on previously published work. [19] [20] [21] Having demonstrated that doxantrazole was effective in decreasing T/HS-induced gut permeability, we then tested whether the protective effects of mast cell inhibition were associated with mucus layer preservation. In this experiment, rats were pretreated with doxantrazole (as previously described) or a normal saline vehicle and then subjected to T/HS. Gut permeability was measured by FD4 permeability, a segment of the terminal ileum was obtained, and mucus loss was measured.
T/HS and Pancreatic Duct Diversion Models
Rats were subjected to either T/HS or T/SS as previously described. 14 Briefly, rats were anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg) and additional intraperitoneal sodium pentobarbital boluses (5 mg/kg) were given as needed throughout the postresuscitation experimental period. A 3-cm midline laparotomy (trauma) was performed, followed by small and large bowel evisceration for 15 minutes. In animals undergoing pancreatic duct ligation and exteriorization, the distal biliary-pancreatic duct was identified and cannulated with polyethylene (PE-10) tubing and externalized. The biliary-pancreatic tube was then secured with a 4-0 silk suture. The proximal duct was then ligated distal to the site of cannulation just proximal to its entrance into the duodenum. In all animals, the small and large intestines were then returned to the abdominal cavity and the abdomen was closed with a running 3-0 silk suture. Blood was withdrawn at a rate of 1 mL/min until the mean arterial pressure reached 30 to 35 mm Hg. The mean arterial pressure was maintained at 30 to 35 mm Hg for 90 minutes by withdrawing or reinfusing the shed blood. At the end of the shock period, the animals were resuscitated by reinfusion of all the shed blood at a rate of 1 mL/min as previously described. 14 The mean arterial pressure returned to the normal level within a few minutes after the animals were resuscitated and remained at that level for the duration of the experiment. In the T/SS group, animals underwent cannulation of vessels and laparotomy but were not subjected to T/HS.
Collection of Mucus Sample and Measurement of Protein Concentration
The distal 30-cm segment of the terminal ileum was identified and transected from the intestinal tract and the underlying mesentery. The intestinal mucus from this sample was collected and processed as previously described. 6 The concentration of protein in the mucus samples was measured by the BCA (bicinchoninic acid) assay (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer's instructions. Protein concentrations are expressed as micrograms per milliliter.
Mucus Structural Change Assays
Nitration of tyrosine residues, a marker for RNI-mediated injury, was measured with a competitive enzyme-linked immunosorbent assay (ELISA) [Nitrotyrosine ELISA (Millipore, Billerica, MA) and 3-Nitrotyrosine ELISA (Abcam, Cambridge, MA)] as previously described. 6 Nitrated tyrosine residues are expressed as nitro-BSA equivalents. 23 Carbonyl derivatives, a marker of reactive oxygen species-mediated damage, were quantified by ELISA (OxiSelect Protein Carbonyl ELISA; Cell Biolabs, San Diego, CA) as previously described. 6 Reactive oxygen species-mediated damage was expressed as protein carbonyl (nanomoles per milligram).
Measurement of Total Antioxidant Capacity
One measure of mucus function is its ability to function as an antioxidant 14 ; thus, mucus sample antioxidant capacity was measured via ELISA (Total Antioxidant Capacity Assay; Abcam) as previously described. 6 Total antioxidant capacity is expressed as trolox equivalents (per nanomoles), the antioxidant capacity of 1 nmol of trolox, which is 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, a standard measurement for antioxidant capacity. 24
Villous Injury and Mucus Coverage
After sacrifice, a 5-cm segment of the terminal ileum was collected for histologic studies. To visualize the mucus layer, the mucosal surface was then covered with 3% Alcian blue, followed by fixation in Carnoy solution for 2 hours. 25 After processing, 5 random fields containing 100 to 250 villi per animal were analyzed in a blinded fashion to quantitate morphologic villous damage; ileal mucus coverage is expressed as the percentage of the villi that were not covered with mucus as previously reported. 25
In Vivo Gut Barrier Permeability
Ileal permeability was measured in vivo using the 4-kD dextran permeability probe FD-4 (Sigma, St Louis, MO), a fluorescentlabeled dextran molecule with an average molecular weight of 3000 to 5000 units as previously reported, and was expressed as the amount of FD-4 found in systemic plasma in nanograms per milliliter. 14
Bacterial Translocation
The mesenteric lymph node complex was harvested, and the level of bacterial translocation was quantified as previously described. 26 
Lung Permeability and BALF Leukocyte Counts
Lung permeability was assessed by permeability to Evans blue dye as previously described. 27 BALF volumes were noted, and cell pellets were resuspended in a fixed volume (100 μL) of phosphate buffered saline. White blood cell counts were performed in resuspended cell pellets using an automated cell counter (Hematrue; Heska Corporation, Loveland, CO).
Lung Injury Score
Three hours after T/HS or T/SS, lungs were harvested by median sternotomy and immediately fixed in 10% buffered formalin solution. After fixation, lung tissue samples were dehydrated, embedded in paraffin blocks, cut into 4-μm thick sections, and stained with hematoxylin-eosin. The slides were read under a standard light microscope, lung injury was scored by the histologic grading scale described by Claridge et al, 28 and the total number of neutrophils were counted. Thirty random fields in each sample were analyzed in a blinded fashion.
Mucosal Mast Cell Identification
Immunodetection of RMCP II was carried out on 10% buffered formalin-fixed section using a monoclonal antibody (Moredun Anima Health, Edinburgh, United Kingdom). Detection was performed with avidin/peroxidase (Vectastain ABC kit; Vector Lab, Burlingame, CA). Sections were counterstained with hematoxylin. Positively stained mast cells were counted and expressed as numbers in 100 villi.
Measurement of RMCP II Levels
Serum samples were taken from all rats at 3 hours after resuscitation or sham resuscitation. RMCP II concentration in the serum and lymph was measured by ELISA using commercial kits (Moredun Anima Health).
Statistical Analysis
The results are expressed as mean ± SEM. Statistical analysis was conducted using Prism-4 software (GraphPad Software, Inc., La Jolla, CA). Unpaired Student t tests and analysis of variance were used for single and group comparisons, respectively. For data sets compared using analysis of variance, the post hoc Newman-Keuls method was used to determine significance between groups. The incidence of bacterial translocation was assessed by the Fisher exact test. Statistical significance was considered achieved at P < 0.05.
RESULTS

Pancreatic Duct Cannulation With Exclusion
T/HS was associated with an increase in gut injury as reflected by an increase in gut permeability and villous injury compared with the T/SS groups (Figs. 1A, B ). In addition, the percentage of villi covered with mucus was reduced in T/HS compared with T/SS rats (Fig. 1C) . In contrast to the T/HS rats, the T/HS rats with PDC were protected and levels of gut permeability, villous injury, and mucus coverage of the villi were similar to that of the T/SS groups (Fig. 1 ).
Because T/HS-induced mucus layer loss is related to an I/Rmediated oxidant injury, 6 and PDC limits T/HS-induced mucus loss, we tested the extent to which PDC would limit T/HS-induced mucus layer oxidation, nitration, and preservation of mucus antioxidant capacity. T/HS was associated with increased mucus oxidant injury as reflected in increased mucus protein carbonyl levels, whereas PDC could abrogate but not prevent mucus oxidation ( Fig. 2A) . A similar pattern was observed for mucus protein nitration, with PDC abrogating but not totally preventing T/HS-induced mucus protein nitration (Fig. 2B) . Likewise, PDC could partially limit the loss of mucus antioxidant activity observed after T/HS (Fig. 2C ).
Administration of HMW-PEG
Because the mucus layer seems to function as a key protective barrier that limits T/HS-induced gut injury and subsequent lung injury, 4 we next tested whether the administration of HMW-PEG, which can function as a mucus surrogate, 11 would limit T/HS-induced gut and/or lung injury. As shown in Figure 3 , the intraluminal administration of HW-PEG prevented the increase in gut permeability (Fig. 3A ) observed after T/HS and T/HS-induced morphologic villous injury ( Fig. 3B ) and bacterial translocation (Fig. 3C ). Because the bacterial intestinal population level is an important variable in bacterial translocation, we measured the effect of HMW-PEG on cecal bacterial population levels and found that the ability of HMW-PEG to decrease bacterial translocation was not associated with changes in cecal bacterial population levels (Fig. 3D ). The administration of HMW-PEG could prevent the T/HS-induced increase in lung permeability (Fig. 4A) and bronchoalveolar white blood cell count (Fig. 4B) . On the basis of in vitro tests showing that HMW-PEG did not decrease trypsin activity, this protective effect of HMW-PEG on gut injury does not seem to be due its ability to interfere with enzymatic activities of luminal trypsin (data not shown).
Intestinal Mast Cell Activation
T/HS was associated with a 4-fold increase in intestinal mast cell numbers (Figs. 5A, B) and an increase in serum and lymph rat mast cell protease II levels (Figs. 5C, D) . This indicates that T/HS is associated with mast cell activation 3 hours after reperfusion. On the basis of these results, we next tested and found that the mucosal mast cell inhibitor, doxantrazole, protected against T/HS-induced increased gut permeability and lung injury (Figs. 6A, B) . In contrast to doxantrazole, the connective tissue nonmucosal mast cell stabilizer, ketotifen, did not protect against T/HS-induced increased gut permeability or lung permeability (Figs. 6C, D) . Although doxantrazole prevented increased T/HS-induced gut permeability, it did not prevent T/HS-induced loss of the intestinal mucus layer (Figs. 7A, B) . This observation suggests that mucus loss is not dependent on mast cell activation.
DISCUSSION
The I/R paradigm has helped clarify the mechanisms through which shock states, including hypoperfusion, are transduced into tissue injury and systemic inflammation. During times of stress or shock, blood is preferentially shunted from the splanchnic circulation into the central circulation to sustain perfusion of vital organs. 29 This makes the gastrointestinal tract quite susceptible to I/R-induced injury. However, unlike most organs, the gut serves as a barrier to the potentially hostile external environment. Not only does the lumen of the gut contain a large number of bacteria and bacterial products but it also contains high concentrations of potentially injurious digestive enzymes. Thus, the normal intestine must be capable of digesting and absorbing nutrients while preventing the escape and systemic spread of intestinal bacteria, bacterial products, and digestive enzymes. An important, yet relatively underappreciated, component of the gut barrier is the mucus layer. The mucus layer facilitates absorption of nutrients and other molecules while preventing bacteria, bacterial products, and digestive enzymes from coming into direct contact with the underlying enterocytes 4 where they could induce injury and inflammation. In fact, basic pharmacologic and physiologic studies of the intestinal barrier have documented that the mucus layer is more important in preventing the escape of luminal factors from the gut than from the tight junctions between enterocytes. 5, 30 Consequently, we previously tested the hypothesis that the loss of the mucus layer significantly contributes to gut barrier failure in conditions associated with splanchnic hypoperfusion and I/R-mediated gut injuries. These prior studies demonstrate that mucus layer loss is associated with increased gut permeability and that anatomic sites of mucus disruption directly correlate with areas of morphologic gut injury. 7, 8, 14, 25 Subsequent studies indicate that the T/HS-induced gut I/R insult leads to oxidative modification and extrusion of the mucus layer into the intestinal lumen, further contributing to loss of gut barrier function. 6 Early pioneering studies performed by Schmid-Schonbein's laboratory 5, 31, 32 and the subsequent work by other groups, including our own, 9, 10 illustrate the important role that intraluminal pancreatic digestive enzymes play in the pathogenesis of shock-induced gut injury and the MODS response. The culmination of such studies led Schmid-Schonbein to propose the autodigestion hypothesis, which postulates that the products of pancreatic enzymatic digestion, rather than the enzymes themselves, lead to systemic inflammation and organ injury. 33 Consequently, the goal of the current work was to integrate these 2 lines of work and test the basic hypothesis that oxidative injury to the mucus layer during I/R is a key initiating factor in mucosal barrier disruption that allows digestive enzymes access into the intestinal wall, thereby initiating an autodigestive response.
Our results documenting that diversion of pancreatic enzymes from the intestinal lumen by PDC prevents T/HS-induced increases in gut permeability and intestinal villous injury validates earlier studies. 10 However, the results from this set of experiments also show that pancreatic enzyme diversion only partially protected against T/HS-induced oxidative and physiologic modifications of the mucus layer. These results have several implications. First, PDC is able to completely prevent gut injury and mucus loss despite the presence of oxidative and nitrosylated modifications to the mucus layer. Second, an intestinal I/R insult is directly responsible for the chemical changes observed in the mucus layer after T/HS. Third, the T/HSinduced systemic I/R injury to the gut is not sufficient to induce demonstrable gut injury and dysfunction in the absence of intraluminal pancreatic proteases. The potential explanation of the synergistic effects of a systemic I/R injury and the role of luminal digestive enzymes in the pathogenesis of T/HS-induced gut injury will need further study. The pancreatic proteases already present in the intestine of the PDL-treated rats subjected to T/HS do not seem to be sufficient by themselves to cause gut injury. The reason for this observation is unclear but may represent a dose-response effect, where a certain minimal amount of pancreatic proteases need to be present during and after the shock state to cause injury to the mucosa. In the absence of additional secretion of pancreatic proteases in the pancreatic duct-ligated animals, the gut luminal level of pancreatic proteases might not have reached sufficiently high concentrations to contribute to gut injury. It is also known that reactive oxygen and nitrogen species damage and degrade mucin molecules, resulting in a loss of viscosity and a decrease in hydrophobicity. 15, 34 The oxidantmediated damage to the mucus layer not only compromises the gut barrier but also increases the susceptibility of the mucins to pancreatic protease cleavage. 35, 36 As a result of these modifications, mucins are less able to prevent translocation of digestive enzymes into the underlying mucosa. 37 Consequently, it seems that the pathogenesis of T/HS-induced gut injury is a multiple-hit phenomenon, whereby the initial insult is an intestinal I/R insult to the mucus layer 6 and the second hit is the intraluminal pancreatic proteases reaching and crossing the layer of enterocytes lining the villi. 38 The protective effect of the mucus layer was further validated by our observation that the enteral administration of HMW-PEG could limit T/HS-induced gut injury and loss of barrier function. PEG with a molecular weight of 15 to 20 kD was tested because it has been previously shown to act as a mucus surrogate and to play a protective role in a lethal gut origin sepsis model, whereas low-molecular-weight PEG (3-5 kD) found in GoLytely was not effective. 11, 13 Although the mechanisms by which HMW-PEG limited gut injury, bacterial translocation, and increased gut permeability after T/HS remain to be determined, certain facts about HMW-PEG are known that could have contributed to its protective effects. First, HMW-PEG has been shown to adhere to enterocytes as globules and decrease bacterial contact and internalization by enterocytes. 39 Second, HMW-PEG can directly bind to bacteria and further decrease their ability to reach and translocate across the gut barrier. 11 Although not explicitly tested, it seems that the ability of HMW-PEG to bind luminal bacteria was likely not responsible for the protective effects seen in the current studies because the intestinal bacterial population levels were similar in both arms. Third, HMW-PEG has been shown to upregulate various components of the barrier-enhancing signal transduction pathway. 13 Furthermore, by modulating the intraluminal compartment, HMW-PEG was efficacious in preventing T/HS-induced acute lung injury. This suggests that the strategy of limiting acute gut injury after T/HS by the oral administration of a mucus surrogate also has potential systemic and clinical benefits. Because these results are consistent with a large body of evidence on gut origin sepsis, 1 they are thus not surprising.
Our results also highlight the important role that mast cell activation and degranulation play in T/HS-induced gut injury. T/HS was associated with mast cell degranulation and the release of the mucosal mast cell-specific tryptase RMCP II. Furthermore, the observation that the mast cell stabilizer doxantrazole, but not ketotifen, prevented T/HS-induced gut and lung injury has physiologic implications because the major action of doxantrazole is on both mucosal and connective tissue mast cells 20, 21 whereas ketotifen affects only connective tissue mast cells. 20 Thus, the differential effects of these 2 mast cell stabilizers are important in implicating intestinal mucosal mast cells as being active participants in T/HS-induced gut injury and gut-induced MODS response. Taken together, our results complement previous studies documenting that chemical mast cell stabilizers limit gut injury in isolated gut I/R and in lipopolysaccharide models of gut injury and that mast cell-deficient rats and mice are relatively resistant to I/R-induced gut injury and the downstream systemic inflammatory response syndrome response. 20, 21, 40, 41 Furthermore, mucosal mast cell activation under conditions associated with gut barrier failure is consistent with their position at host-environment interfaces where they can serve as first responders to invading pathogens and act as cell stress signals. Although additional research is needed to further investigate the protective effect of gut-specific mast cell inhibition in the pathogenesis of gut-mediated sepsis, this study clearly documents an association between T/HS-mediated I/R intestinal injury and mast cell activation.
CONCLUSIONS
We hypothesize that T/HS, or other conditions associated with splanchnic hypoperfusion, induces an intestinal I/R injury that results in a mild enterocyte injury and an oxidant-mediated injury to the intestinal mucus layer. Although the I/R injury is not independently sufficient to completely disrupt the gut barrier, the chemically modified mucus is sufficiently modified to allow further mucin degradation by intraluminal water-soluble pancreatic proteases. This allows the pancreatic proteases, and other luminal factors (such as bacteria and bacterial products), to cross the enterocyte barrier, reach the submucosal space, and initiate an injurious response that is likely mediated, in part, by mucosal mast cells. Thus, translocated luminal factors seem to exacerbate the magnitude of gut injury and contribute to the development of MODS.
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